Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet
- 27 February 2004
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 315 (1), 187-195
- https://doi.org/10.1016/j.bbrc.2004.01.038
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 22 references indexed in Scilit:
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneHepatology, 2003
- Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitisJournal of Hepatology, 2003
- Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinomaGastroenterology, 2002
- Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cellsGastroenterology, 2000
- Peroxisome proliferator-activated receptor ? transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cellsHepatology, 2000
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisHepatology, 1999
- Thiazolidinediones in the Treatment of Insulin Resistance and Type II DiabetesDiabetes, 1996
- Nonalcoholic steatohepatitis: An expanded clinical entityGastroenterology, 1994
- The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 yearsHepatology, 1990
- Nonalcoholic steatohepatitis: A study of 49 patientsHuman Pathology, 1989